Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiondVax secures $2.8m investment from Marius Nacht fund
Upon completion of the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of BiondVax. Angels Investments is owned by Check Point co-founder and
Upon completion of the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of BiondVax. Angels Investments is owned by Check Point co-founder and
The deal, which was signed in June 2016, includes the transfer of Sanofi’s ownership of the €11.4bn Merial animal health business to Boehringer in return for the latter's
Following a preliminary review of the company's NDA for Xaracoll, filed in October 2016, the FDA concluded that the application was not sufficiently complete to allow for a more
The REACH-1 phase 2 trial is assessing ruxolitinib in combination with corticosteroids It has a primary endpoint defined as overall response rate at day 28 of the single-cohort clinical trial. Some
The Pennsylvania based global pharma rolled out Methylphenidate Hydrochloride extended-release tablets USP, 18mg, 27mg, 36mg and 54mg, which are indicted for treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The brands bought by Zydus Healthcare in the deal are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten which are expected to strengthen the global pharmaceutical group’s portfolio in
Effi-7, an antagonist of the interleukin-7 receptor, is intended to treat patients suffering from invalidating autoimmune pathologies. The deal is inclusive of an upfront payment of €10.25m by
Kubota Pharmaceutical will hold 51% stake while the remainder will be held by SBI in the unnamed joint venture which will organize and manage special purpose entities in
As part of the deal, Pfizer has acquired the commercialisation and development rights of AstraZeneca’s approved antibiotics Merrem, Zinforo and Zavicefta as well as its ATM-AVI and CXL
Patients receiving emicizumab showed a statistically significant reduction in bleeds over time compared with those not being treated with it. The treatment also met secondary goals of reducing